HealthLatest News

European Union Authorizes Sale Of Antiviral Drug Remdesivir Against Coronavirus

What Happened?

The European Commission authorized on Friday provisionally the sale in the European Union (EU) of the antiviral drug remdesivir for the treatment of patients with coronavirus, after the approval of the European Medicines Agency.

The community executive granted “a conditional marketing authorization for the medicine remdesivir, making it the first medicine authorized at the EU level for the treatment of COVID-19,” it announced in a statement.

Conditional marketing authorization is reserved in the EU for those drugs whose benefits are estimated to be greater than their risks, despite not yet having complete data. Its duration is one year renewable.

For Which Patients Can It Be Used?

The molecule from the American laboratory Gilead Sciences was developed to treat patients with Ebola hemorrhagic fever, without success, but during a trial in the United States it showed some efficacy against Covid-19.

According to that study, patients with this disease and treated with remdesivir recover about four days earlier than the other patients. Its use has already been authorized in emergency cases in the United States and Japan.

In its recommendation, prior to the authorization of the Commission with the approval of the 27 European countries, the EMA proposes its use for adults and adolescents from 12 years old who suffer from pneumonia and need oxygen.

What Is The Price of The Medicine?

According to the biopharmaceutical Gilead Sciences, it will charge the Government of the United States and other developed countries $390 dollars for each dose.

With this, a standard five-day treatment would cost $ 2,340 dollars

Meanwhile, in 127 other poor or middle-income countries, Gilead allowed generic manufacturers to supply the drug.

Price For Private Insurance Companies And Other Payers

The value of $390 per dose is for government entities, and once the supply is less and Gilead begins selling the antiviral through normal distribution channels, the price for private insurance companies and other commercial payers will be $520 dollars per dose ($ 427,128 Chilean pesos).

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close